- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00006812
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Phase II Evaluation Of Capecitabine In Recurrent Platinum-Sensitive Ovarian Or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent ovarian epithelial or primary peritoneal cavity cancer.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- Determine the antitumor activity of capecitabine in patients with recurrent, platinum-sensitive ovarian epithelial or primary peritoneal cavity cancer.
- Determine the nature and degree of toxicity of this drug in this patient population.
OUTLINE: This is a multicenter study.
Patients receive oral capecitabine twice daily for 14 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study within 6-12 months.
Studietyp
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35294-3300
- University of Alabama at Birmingham Comprehensive Cancer Center
-
-
California
-
Los Angeles, California, Förenta staterna, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Angeles, California, Förenta staterna, 90033-0804
- USC/Norris Comprehensive Cancer Center and Hospital
-
Orange, California, Förenta staterna, 92868
- Chao Family Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80010
- University of Colorado Cancer Center
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- Rush-Presbyterian-St. Luke's Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202-5289
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242-1009
- Holden Comprehensive Cancer Center at the University of Iowa
-
-
Maryland
-
Bethesda, Maryland, Förenta staterna, 20892
- Radiation Oncology Branch
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02111
- Tufts University School of Medicine
-
Worcester, Massachusetts, Förenta staterna, 01655
- University of Massachusetts Memorial Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- University of Minnesota Cancer Center
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Columbia, Missouri, Förenta staterna, 65203
- Ellis Fischel Cancer Center - Columbia
-
Saint Louis, Missouri, Förenta staterna, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Camden, New Jersey, Förenta staterna, 08103
- Cooper Hospital/University Medical Center
-
-
New York
-
Brooklyn, New York, Förenta staterna, 11203
- State University of New York Health Science Center at Brooklyn
-
New York, New York, Förenta staterna, 10021
- Memorial Sloan-Kettering Cancer Center
-
Stony Brook, New York, Förenta staterna, 11790-7775
- State University of New York Health Sciences Center - Stony Brook
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham, North Carolina, Förenta staterna, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Förenta staterna, 27157-1082
- Comprehensive Cancer Center at Wake Forest University
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44195
- Cleveland Clinic Taussig Cancer Center
-
Columbus, Ohio, Förenta staterna, 43210-1240
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73190
- University of Oklahoma College of Medicine
-
-
Pennsylvania
-
Abington, Pennsylvania, Förenta staterna, 19001
- Abington Memorial Hospital
-
Hershey, Pennsylvania, Förenta staterna, 17033
- Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, Förenta staterna, 19107-5541
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4N2
- Tom Baker Cancer Center - Calgary
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
- Histologically proven recurrent ovarian epithelial or primary peritoneal cavity cancer
Measurable disease
- At least 1 unidimensionally measurable lesion
- Ascites and pleural effusions are not considered measurable disease
Prior therapy must include 1 platinum-based chemotherapy regimen for primary disease containing carboplatin, cisplatin, or another organoplatinum compound
- Treatment-free interval of 6-12 months after response to platinum therapy
- Not eligible for higher priority GOG protocol
PATIENT CHARACTERISTICS:
Age:
- Any age
Performance status:
- GOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least lower limit of normal
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGOT no greater than 2.5 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
Renal:
- Creatinine clearance at least 50 mL/min
Other:
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No neuropathy (sensory and motor) greater than grade 1
- No other malignancy within the past 5 years except nonmelanoma skin cancer
- No concurrent active infection requiring antibiotics
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 3 weeks since prior biologic or immunologic therapy
- No concurrent prophylactic filgrastim (G-CSF)
Chemotherapy:
- See Disease Characteristics
- If no prior therapy with paclitaxel, a second regimen including paclitaxel allowed
- No prior capecitabine or fluorouracil
- No prior chemotherapy for recurrent or persistent disease, including pretreatment with initial chemotherapy regimens
- Recovered from prior chemotherapy
Endocrine therapy:
- At least 1 week since prior hormonal therapy directed at malignant tumor
- Concurrent continuation of hormone replacement therapy allowed
Radiotherapy:
- At least 3 weeks since prior radiotherapy and recovered
- No prior radiotherapy to site(s) of measurable disease
- No prior radiotherapy to more than 25% of bone marrow
Surgery:
- Recovered from prior surgery
Other:
- No prior cancer treatment that would preclude study therapy
- No concurrent amifostine or other protective reagents
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Agustin Garcia, MD, University of Southern California
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CDR0000068330
- GOG-0146L
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Äggstockscancer
-
Ann & Robert H Lurie Children's Hospital of ChicagoOkändCystektomi | Godartade cystor Ovarian | Torsion | Maligna cystor OvarianFörenta staterna
-
Assistance Publique - Hôpitaux de ParisAktiv, inte rekryterandeOkomplicerad Tubo Ovarian AbscessFrankrike
-
Peking University Third HospitalHar inte rekryterat ännuOvarian clear cell carcinoma
-
Dansk FertilitetsklinikOkändKvinnlig infertilitet | Hypogonadism; OvarianDanmark
-
University Health Network, TorontoAvslutad
-
AstraZenecaAvslutadOvarian, Äggledaren, Peritoneal cancer, P53 MutationFörenta staterna, Kanada, Nederländerna
-
M.D. Anderson Cancer CenterGSK Pharma; LixteRekryteringOvarian clear cell carcinomaFörenta staterna
-
National University Hospital, SingaporeOkändOvarian clear cell carcinomaSingapore
-
Tongji HospitalWuhan University; Henan Cancer Hospital; Qilu Hospital of Shandong University och andra samarbetspartnersRekryteringOvarian clear cell carcinomaKina
-
SpringWorks Therapeutics, Inc.Aktiv, inte rekryterandeÄggstockscancer | Ovarian granulosa celltumör | Ovarian Granulosa-Stromal tumörFörenta staterna, Kanada, Polen
Kliniska prövningar på capecitabin
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRekrytering
-
Hoffmann-La RocheAvslutadBröstcancer, kolorektal cancerNya Zeeland, Australien, Storbritannien
-
Binghe XuHoffmann-La RocheOkändHudsjukdomar | Neoplasmer efter plats | Bröstneoplasmer | Bröstsjukdomar | Neoplasma MetastasKina
-
Jules Bordet InstituteAvslutadBröstcancer | Äldre patienterBelgien
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityJiangsu HengRui Medicine Co., Ltd.Rekrytering
-
Samsung Medical CenterAvslutadAvancerat eller återkommande esofageal skivepitelcancerKorea, Republiken av
-
Fudan UniversityAvslutadMetastaserad bröstcancerKina
-
Jiangxi Provincial Cancer HospitalRekryteringNasofaryngealt karcinom | Underhållsterapi | HögriskcancerKina
-
Huazhong University of Science and TechnologyOkänd
-
Jiangsu HengRui Medicine Co., Ltd.OkändHER2 positiv metastaserande bröstcancerKina